



Graphical Review

Inputs and outputs of poly(ADP-ribosyl)ation: Relevance to oxidative stress

Csaba Hegedűs^a, László Virág^{a,b,*}^a Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Nagyerdei Krt. 98., H-4032 Debrecen, Hungary^b MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary

ARTICLE INFO

Article history:

Received 25 July 2014

Accepted 10 August 2014

Available online 21 August 2014

Keywords:

Poly(ADP-ribosyl)ation

PARP1

Oxidative stress

Cell death

Necroptosis

Apoptosis

ABSTRACT

Oxidative stress can cause DNA breaks which induce activation of the DNA nick sensor enzyme poly (ADP-ribose) polymerase-1 (PARP-1), part of the 17 member PARP enzyme family. PARP-1 modifies target proteins by attaching to them several NAD-derived ADP-ribose units forming poly(ADP-ribose) (PAR) polymers. PARylation controls many cellular processes while intense PARylation may also lead to cell death by various mechanisms. Here we summarize the modes of activation, inhibitors and modulators of PARP-1 and review the cellular functions regulated by the enzyme.

© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/3.0/>).

Contents

Introduction.....	1
Routes for PARP-1 activation	1
Inhibitors and modulators of PARP-1.....	2
Cellular effects of PARP-1 activation.....	3
Conflicts of interest.....	4
Acknowledgments.....	4
References.....	4

Introduction

Poly(ADP-ribosyl)ation (PARylation) is a protein modification catalyzed by poly(ADP-ribose) polymerase (PARP) enzymes. The enzyme family was created based on database screening using the highly conserved PARP signature motif. Whereas the PARP enzyme family consists of 17 members [1], only three of these enzymes can be considered as bona fide PARPs while the other family members function as mono(ADP-ribosyl) transferases or their enzymatic activity has not yet been characterized. PARylation requires NAD as substrate and this energy metabolite is cleaved into nicotinamide and ADP-ribose by active PARP enzymes. In turn, PARPs attach the

first ADP-ribose unit to appropriate substrates and then generate further ADP-ribose units by repeated NAD cleavage and polymerize ADP-ribose moieties [2].

Here we review the mechanisms by which activity of PARP-1 can be stimulated, inhibited or modulated. We also aim to summarize the cellular functions that are regulated by PARP-1.

Routes for PARP-1 activation

PARP-1 has originally been described as a DNA nick sensor enzyme activated by DNA single and double strand breaks [3]. DNA damage-induced PARP-1 activation is considered as the classical route for the activation of the enzyme (Fig. 1). PARP-1 binds to broken DNA ends via the zinc finger motives found in the N-terminal DNA binding domain. Reactive oxygen and nitrogen

* Corresponding author at: Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Nagyerdei Krt. 98., H-4032 Debrecen, Hungary.

E-mail address: lvirag@med.unideb.hu (L. Virág).




Fig. 1. Activation of PARP-1. The nuclear enzyme PARP-1 can bind to DNA breaks resulting in the activation of the enzyme. DNA breaks are caused either by direct attacks by ROS, RNS or ionizing radiation or may form indirectly when the DNA repair machinery introduces breaks into the DNA strands following e.g. alkylating DNA damage. Binding to non-B DNA structures such as bent or cruciform DNA or four-way junctions may also lead to PARP-1 activation. DNA independent activation mechanisms have also been described for PARP-1. These include protein–protein interactions or covalent modifications (e.g. mono-ADP-ribosylation, acetylation or phosphorylation) (for details and references see text).

species (ROS and RNS, respectively) activate PARP-1 via this route as many ROS/RNS species are capable of causing DNA single strand breaks [4]. Ionizing radiations may also cause DNA breaks either directly (e.g. alpha particles or neutrons which have high linear energy transfer) or indirectly (via interaction with water resulting in the production of hydroxyl radicals). Moreover, repair of damage caused by alkylating agents [e.g. N-methyl-N-nitro-N-nitrosoguanidine (MNNG), N-nitroso-N-methylurea (MNU), temozolomide, and carmustine] also feed into this route as DNA repair machineries (e.g. base excision repair and nucleotide excision repair) introduce cuts (single or double strand breaks) leading to PARP-1 activation [5].

The findings that stimuli other than broken DNA can also activate PARP-1 (Fig. 1) led to a paradigm shift in the investigation of the enzyme [6]. Lonskaya et al. showed that PARP-1 can bind to non-B DNA structures (three- and fourway junctions, hairpins, cruciforms and stably unpaired regions) resulting in activation of the enzyme [7]. Moreover, the enzyme may be activated by interactions with partner proteins (Fig. 1). For example interaction with the N-terminal tail of histone 4 has been shown to activate PARP-1 [8]. Moreover, physical interaction between PARP-1 and the phosphorylated form of Erk MAP kinase also activates PARP-1 [9,10]. Furthermore, protein modifications, e.g. phosphorylation by certain protein kinases such as CamKII delta [11], mono-ADP-ribosylation by SIRT6 [12,13] or PARP-3 [14] or acetylation can also stimulate PARP-1 activity [15] (Fig. 1). Of note, a basal phosphorylation by an unknown kinase was found to be required for PARP-1 activity [16]. SIRT6 a mammalian homolog of the yeast Sir2 deacetylase has been shown to be recruited to the sites of oxidative DNA damage (double strand breaks) where it associates with PARP1 and activates it by mono-ADP-ribosylation [13]. PARP-3 can also catalyze activating mono(ADP-ribosyl)ation of PARP-1 but this reaction takes place in the absence of DNA [14]. PARP-1 has also been shown to be a target of acetylation [17]. Acetylation of PARP-1 may contribute to the maintenance of the active state of the enzyme as deacetylation by SIRT-1 downregulated the activity of PARP-1 [15].

Inhibitors and modulators of PARP-1

Several classes of compounds with PARP inhibitory properties have been developed and characterized. Their discussion would go way beyond the scope of this review so we only refer to excellent reviews on PARP inhibitors and their therapeutic potentials [18–20]. In addition to bona fide PARP inhibitors several other molecules have been demonstrated to exhibit PARP inhibitory effects [21,22]. These include arsenite [23] (Fig. 2), tetracyclines [24], flavones, flavonoles [25], purines [26], unsaturated fatty acids [21], vitamin D3 [27], vitamin A and vitamin K [21]. However, the biological relevance of the PARP inhibitory properties of these exogenous or endogenous molecules with special regard to the relationship between their cellular concentrations and their K_i values remains to be determined.

A much more interesting issue is the interference between certain signaling events and PARP activation (Fig. 2). Above we discussed phosphorylation as one of the PARP-1 activating stimuli. However, phosphorylation of PARP-1 by kinases such as DNA-PK [28] or protein kinase C has been shown to inhibit the activity of the enzyme [29,30]. This finding translates to cellular consequences as it has later been demonstrated that activation of PKC by phorbol esters led to inhibition of oxidative stress-induced PARP activation and resulted in suppressed PARP-dependent cytotoxicity [31]. Calcium signal, a temporarily elevated cytosolic calcium concentration may also be required for oxidative stress-induced PARP activation [32,33]. Calcium chelators prevent oxidative stress-induced PARP-1 activation (Fig. 2), however the exact nature of the relationship between the calcium signal and PARP activity remains elusive. On the one hand PARP activity has been shown to depend on calcium [34], while this relationship is partly indirect: calcium chelation also suppressed oxidative-stress-induced DNA breakage suggesting that calcium also plays a role at a more proximal step of the oxidative stress-DNA breakage-PARP-1




Fig. 2. Inhibition of PARP-1. PARP-1 is an attractive pharmacological target in various diseases and therefore several classes of small molecule PARP inhibitors (not shown) have been developed and tested successfully in cellular assays and animal models of diseases ranging from cancer, ischemia-reperfusion injury, stroke, sepsis to shock. Several biomolecules such as flavones, flavonols, vitamins D3, A and K, purines and even unsaturated fatty acids have been described to possess PARP inhibitory activities. Other bioactive compounds such as arsenite or tetracyclines also inhibit PARP-1. Inhibiting PARP activating signals such as calcium signal, activating phosphorylation by certain kinases or zinc signaling may also lead to downregulation of PARP-1 activity. Of note, in the case of zinc chelators, it is not yet clear whether interference with the signaling role of zinc or simply stripping off structural zinc ions from PARP-1 results in enzyme inhibition. Some phosphorylation events are not PARP-1 activating signals but have inhibitory effects on the enzyme (for details and references see text).

activation-cell death pathway [32]. To make the situation even more complex, a late mitochondrial (?) calcium signal can also be detected in oxidatively stressed cells and this late signal responds well to PARP-1 inhibition or knockout [50].

Until recently calcium was the only ion considered to serve a second messenger role. However, similar roles have later been assigned to magnesium and zinc ions [36]. Interestingly, zinc chelation suppressed PARP activation and subsequent cell death in oxidatively stressed cells (Fig. 2) suggesting a possible link between this transition metal ion and the enzyme [37]. PARP-1 binds to DNA via its zinc fingers so it may be plausible to hypothesize that the zinc chelator withdraws the structure stabilizing zinc ion from the zinc finger motives resulting in enzyme inhibition. In light of the increasingly recognized signaling role of zinc, however, a scenario described above for calcium may not be excluded either. According to this hypothesis awaiting experimental confirmation, zinc signaling may converge on PARP-1 triggering its activation.

The role of several metabolites connected to PARP-1 including its substrate (NAD), a key metabolite required for NAD synthesis (ATP) and a product (nicotinamide) should not be disregarded as they have also been shown to affect PARP activity [38]. Discussion of these interrelationships, however, would go beyond the scope of this review.

Cellular effects of PARP-1 activation

The effects of PARP-1 and PARylation are translated to cellular responses in various different ways (Fig. 3). On the one hand PARylation of PARP-1 (auto-PARylation) and other substrate proteins (hetero-PARylation) alter the physicochemical properties of the targets resulting in activation, inhibition or intracellular translocation of the modified proteins. Moreover, non-covalent

binding of free or protein-bound polymer to proteins bearing one of the PAR-binding motives also affects the function of the targeted protein. Furthermore, PARP-1 can activate protein partners via protein-protein interactions and by substrate competition with other NAD-utilizing enzymes such as members of the Sir2 family of NAD-dependent deacetylases (Fig. 3).

The consequences of PARylation, PAR signaling, interaction of PARP-1 with partner proteins and substrate competition affect many cellular events ranging from genome organization [3,39], transcription [39,40], replication [41] to DNA repair [42]. These molecular pathways form the basis of such vital cellular functions such as cell proliferation [43], differentiation [44–47], metabolism and necrotic cell death [35,48,49,51–53]. The combination of cytoprotective effects and inhibition of transcription of inflammatory mediators are considered central factors responsible for the beneficial effects of PARP inhibitors as demonstrated in various models of inflammation and tissue injury [54,55,19].

From these intertwining networks of molecular events and cellular functions here we would like to highlight one aspect bearing the highest relevance to oxidative stress: regulation of oxidative stress-induced cell death. The generally held view that in severe oxidative stress situations unrepairable DNA damage induces excessive PAR production and consequent NAD^+ and ATP consumption has recently been challenged. Dawson's group has elegantly demonstrated [56] that PARP-1-mediated inhibition of glycolysis is not simply due to NAD consumption by PARP-1 but results from PAR binding to hexokinase the first regulated enzyme in the glycolytic pathway causing hexokinase inhibition (Fig. 3) which slows down glycolysis. The PARP-mediated cell death pathway is amenable to pharmacological intervention as proven by numerous studies reporting cytoprotection by PARP inhibitor treatment applied in various animal models of oxidative stress-related diseases [19,55].




Fig. 3. Cellular roles of PARylation. PARP-1 regulates molecular events by four mechanisms: (a) PARylation of target proteins; (b) non-covalent binding of free or protein-bound PAR polymer to target proteins; (c) protein–protein interactions between PARP-1 and partner proteins; and (d) modulation of cellular levels of NAD and ATP. These molecular events form the basis for the cellular roles of PARP-1 in the regulation of chromatin organization, transcription, replication, DNA repair and metabolism. Combinations of these cellular effects are responsible for the regulatory roles of PARP-1 in cell differentiation, proliferation and cell death (for details and references see text).

Conflicts of interest

Authors declare no conflict of interest.

Acknowledgments

This research was supported by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TÁMOP 4.2.4.A/2-11/1-2012-0001 ‘National Excellence Program’. Direct costs of this study were supported by the Hungarian Science Research Fund (OTKA K82009 and K112336).

References

- [1] H. Otto, P.A. Reche, et al., In silico characterization of the family of parp-like poly(ADP-ribosyl)transferases (pARTs), *BMC Genomics* 6 (2005) 139. <http://dx.doi.org/10.1186/1471-2164-6-139> 16202152.
- [2] Y. Nishizuka, K. Ueda, et al., Enzymic adenosine diphosphate ribosylation of histone and poly adenosine diphosphate ribose synthesis in rat liver nuclei, *Journal of Biological Chemistry* 243 (13) (1968) 3765–3767 4298073.
- [3] M.Y. Kim, S. Mauro, et al., NAD⁺-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1, *Cell* 119 (6) (2004) 803–814. <http://dx.doi.org/10.1016/j.cell.2004.11.002> 15607977.
- [4] C. Nossier, S. Coppola, et al., Possible involvement of poly(ADP-ribosyl) polymerase in triggering stress-induced apoptosis, *Experimental Cell Research* 212 (2) (1994) 367–373. <http://dx.doi.org/10.1006/excr.1994.1156> 8187831.
- [5] H. Juárez-Salinas, J.L. Sims, et al., Poly(ADP-ribose) levels in carcinogen-treated cells, *Nature* 282 (5740) (1979) 740–741. <http://dx.doi.org/10.1038/282740a0> 229416.
- [6] A. Bürkle, L. Virág, Poly(ADP-ribose): PARadigms and PARadoxes, *Molecular Aspects of Medicine* 34 (6) (2013) 1046–1065. <http://dx.doi.org/10.1016/j.mam.2012.12.010> 23290998.
- [7] I. Lonskaya, V.N. Potaman, et al., Regulation of poly(ADP-ribose) polymerase-1 by DNA structure-specific binding, *Journal of Biological Chemistry* 280 (17) (2005) 17076–17083. <http://dx.doi.org/10.1074/jbc.M413483200> 15737996.
- [8] A. Pinnola, N. Naumova, et al., Nucleosomal core histones mediate dynamic regulation of poly(ADP-ribose) polymerase 1 protein binding to chromatin and induction of its enzymatic activity, *Journal of Biological Chemistry* 282 (44) (2007) 32511–32519. <http://dx.doi.org/10.1074/jbc.M705989200> 17827147.
- [9] M. Cohen-Armon, PARP-1 activation in the ERK signaling pathway, *Trends in Pharmacological Sciences* 28 (11) (2007) 556–560. <http://dx.doi.org/10.1016/j.tips.2007.08.005> 17950909.
- [10] M. Cohen-Armon, L. Visochek, et al., DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation, *Molecular Cell* 25 (2) (2007) 297–308. <http://dx.doi.org/10.1016/j.molcel.2006.12.012> 17244536.
- [11] B.G. Ju, D. Solum, et al., Activating the PARP-1 sensor component of the groucho/TLE1 corepressor complex mediates a CaMK kinase II-dependent neurogenic gene activation pathway, *Cell* 119 (6) (2004) 815–829. <http://dx.doi.org/10.1016/j.cell.2004.11.017> 15607978.
- [12] M. Van Meter, Z. Mao, et al., Repairing split ends: SIRT6, mono-ADP ribosylation and DNA repair, *Aging* 3 (9) (2011) 829–835 21946623.

- [13] Z. Mao, C. Hine, et al., SIRT6 promotes DNA repair under stress by activating PARP1, *Science* (New York, N.Y.) 332 (6036) (2011) 1443–1446. <http://dx.doi.org/10.1126/science.1202723> 21680843.
- [14] O. Loseva, A.S. Jemth, et al., PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA, *Journal of Biological Chemistry* 285 (11) (2010) 8054–8060. <http://dx.doi.org/10.1074/jbc.M109.077834> 20064938.
- [15] S.B. Rajamohan, V.B. Pillai, et al., SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1, *Molecular and Cellular Biology* 29 (15) (2009) 4116–4129. <http://dx.doi.org/10.1128/MCB.00121-09> 19470756.
- [16] J.P. Gagné, X. Moreel, et al., Proteomic investigation of phosphorylation sites in poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase, *Journal of Proteome Research* 8 (2) (2009) 1014–1029. <http://dx.doi.org/10.1021/pr800810n> 19105632.
- [17] P.O. Hassa, S.S. Haenni, et al., Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription, *Journal of Biological Chemistry* 280 (49) (2005) 40450–40464. <http://dx.doi.org/10.1074/jbc.M507553200> 16204234.
- [18] M. Banasik, H. Komura, et al., Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase, *Journal of Biological Chemistry* 267 (3) (1992) 1569–1575 1530940.
- [19] L. Virág, C. Szabó, The therapeutic potential of poly(ADP-ribose) polymerase inhibitors, *Pharmacological Reviews* 54 (3) (2002) 375–429. <http://dx.doi.org/10.1124/pr.54.3.375> 12223530.
- [20] P. Jagtap, C. Szabó, Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors, *Nature Reviews: Drug Discovery* 4 (5) (2005) 421–440. <http://dx.doi.org/10.1038/nrd1718> 15864271.
- [21] M. Banasik, H. Komura, et al., Inhibition of poly(ADP-ribose) synthetase by unsaturated fatty acids, vitamins and vitamin-like substances, *FEBS Letters* 263 (2) (1990) 222–224. [http://dx.doi.org/10.1016/0014-5793\(90\)81378-2](http://dx.doi.org/10.1016/0014-5793(90)81378-2) 2139856.
- [22] M. Banasik, T. Stedeford, et al., Natural inhibitors of poly(ADP-ribose) polymerase-1, *Molecular Neurobiology* 46 (1) (2012) 55–63. <http://dx.doi.org/10.1007/s12035-012-8257-x> 22476980.
- [23] J.W. Yager, J.K. Wiencke, Inhibition of poly(ADP-ribose) polymerase by arsenite, *Mutation Research* 386 (3) (1997) 345–351. [http://dx.doi.org/10.1016/S1383-5742\(97\)00011-2](http://dx.doi.org/10.1016/S1383-5742(97)00011-2) 9219571.
- [24] C.C. Alano, T.M. Kauppinen, et al., Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations, *Proceedings of the National Academy of Sciences of the United States of America* 103 (25) (2006) 9685–9690. <http://dx.doi.org/10.1073/pnas.0600554103> 16769901.
- [25] L. Geraets, H.J. Moonen, et al., Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells, *Journal of Nutrition* 137 (10) (2007) 2190–2195 17884996.
- [26] L. Virág, C. Szabó, Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death, *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology* 15 (1) (2001) 99–107. <http://dx.doi.org/10.1096/fj.00-0299com> 11149897.
- [27] J.G. Mabley, R. Wallace, et al., Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D, *International Journal of Molecular Medicine* 19 (6) (2007) 947–952 17487428.
- [28] Y. Ariumi, M. Masutani, et al., Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent protein kinase in vitro, *Oncogene* 18 (32) (1999) 4616–4625. <http://dx.doi.org/10.1038/sj.onc.1202823> 10467406.
- [29] Y. Tanaka, S.S. Koide, et al., Poly (ADP-ribose) synthetase is phosphorylated by protein kinase C in vitro, *Biochemical and Biophysical Research Communications* 148 (2) (1987) 709–717. [http://dx.doi.org/10.1016/0006-291X\(87\)90934-X](http://dx.doi.org/10.1016/0006-291X(87)90934-X) 3120711.
- [30] P.I. Bauer, G. Farkas, et al., Inhibition of DNA binding by the phosphorylation of poly ADP-ribose polymerase protein catalysed by protein kinase C, *Biochemical and Biophysical Research Communications* 187 (2) (1992) 730–736. [http://dx.doi.org/10.1016/0006-291X\(92\)91256-P](http://dx.doi.org/10.1016/0006-291X(92)91256-P) 1530631.
- [31] C. Hegedűs, P. Lakatos, et al., Protein kinase C protects from DNA damage-induced necrotic cell death by inhibiting poly(ADP-ribose) polymerase-1, *FEBS Letters* 582 (12) (2008) 1672–1678. <http://dx.doi.org/10.1016/j.febslet.2008.04.023> 18439913.
- [32] L. Virág, G.S. Scott, et al., Requirement of intracellular calcium mobilization for peroxynitrite-induced poly(ADP-ribose) synthetase activation and cytotoxicity, *Molecular Pharmacology* 56 (4) (1999) 824–833 10496967.
- [33] E. Bakondi, M. Gönczi, et al., Role of intracellular calcium mobilization and cell-density-dependent signaling in oxidative-stress-induced cytotoxicity in HaCaT keratinocytes, *Journal of Investigative Dermatology* 121 (1) (2003) 88–95. <http://dx.doi.org/10.1046/j.1523-1747.2003.12329.x> 12839568.
- [34] E. Kun, E. Kirsten, et al., Regulation of the enzymatic catalysis of poly(ADP-ribose) polymerase by dsDNA, polyamines, Mg²⁺, Ca²⁺, histones H1 and H3, and ATP, *Biochemistry* 43 (1) (2004) 210–216. <http://dx.doi.org/10.1021/bi0301791> 14705947.
- [35] L. Virág, G.S. Scott, et al., Peroxynitrite-induced thymocyte apoptosis: the role of caspases and poly(ADP-ribose) synthetase (PARS) activation, *Immunology* 94 (3) (1998) 345–355. <http://dx.doi.org/10.1046/j.1365-2567.1998.00534.x> 9767416.
- [36] B. Chaigne-Delalande, M.J. Lenardo, Divalent cation signaling in immune cells, *Trends in Immunology* 35 (7) (2014) 332–344. <http://dx.doi.org/10.1016/j.it.2014.05.001> 24932518.
- [37] L. Virág, C. Szabó, Inhibition of poly(ADP-ribose) synthetase (PARS) and protection against peroxynitrite-induced cytotoxicity by zinc chelation, *British Journal of Pharmacology* 126 (3) (1999) 769–777. <http://dx.doi.org/10.1038/sj.bjp.0702332> 10188990.
- [38] J.S. Ungerstedt, M. Blömbäck, et al., Nicotinamide is a potent inhibitor of proinflammatory cytokines, *Clinical and Experimental Immunology* 131 (1) (2003) 48–52 12519385.
- [39] W.L. Kraus, J.T. Lis, PARP goes transcription, *Cell* 113 (6) (2003) 677–683. [http://dx.doi.org/10.1016/S0092-8674\(03\)00433-1](http://dx.doi.org/10.1016/S0092-8674(03)00433-1) 12809599.
- [40] W.L. Kraus, M.O. Hottiger, PARP-1 and gene regulation: Progress and puzzles, *Molecular Aspects of Medicine* 34 (6) (2013) 1109–1123. <http://dx.doi.org/10.1016/j.mam.2013.01.005> 23357755.
- [41] F. Dantzer, H.P. Nasheuer, et al., Functional association of poly(ADP-ribose) polymerase with DNA polymerase alpha-primase complex: a link between DNA strand break detection and DNA replication, *Nucleic Acids Research* 26 (8) (1998) 1891–1898. <http://dx.doi.org/10.1093/nar/26.8.1891> 9518481.
- [42] G. de Murcia, J. Ménissier de Murcia, Poly(ADP-ribose) polymerase: a molecular nick-sensor, *Trends in Biochemical Sciences* 19 (4) (1994) 172–176 8016868.
- [43] J. Ménissier-de Murcia, M. Mark, et al., Early embryonic lethality in PARP-1 Atm double-mutant mice suggests a functional synergy in cell proliferation during development, *Molecular and Cellular Biology* 21 (5) (2001) 1828–1832. <http://dx.doi.org/10.1128/MCB.21.5.1828-1832.2001> 11238919.
- [44] M. Bhatia, J.B. Kirkland, et al., Modulation of poly(ADP-ribose) polymerase during neutrophilic and monocytic differentiation of promyelocytic (NB4) and myelocytic (HL-60) leukaemia cells, *Biochemical Journal* 308 (1) (1995) 131–137 7755555.
- [45] M. Masutani, T. Nozaki, et al., Involvement of poly(ADP-ribose) polymerase in trophoblastic cell differentiation during tumorigenesis, *Mutation Research* 477 (1–2) (2001) 111–117 11376692.
- [46] A. Robaszekiewicz, K. Erdélyi, et al., Hydrogen peroxide-induced poly(ADP-ribose)ylation regulates osteogenic differentiation-associated cell death, *Free Radical Biology and Medicine* 53 (8) (2012) 1552–1564. <http://dx.doi.org/10.1016/j.freeradbiomed.2012.08.567> 22940495.
- [47] A. Robaszekiewicz, Z. Valkó, et al., The role of p38 signaling and poly(ADP-ribose)ylation-induced metabolic collapse in osteogenic differentiation-coupled cell death, *Free Radical Biology and Medicine* (2014). <http://dx.doi.org/10.1016/j.freeradbiomed.2014.07.027>.
- [48] N.A. Berger, J.L. Sims, et al., Poly(ADP-ribose) polymerase mediates the suicide response to massive DNA damage: Studies in normal and DNA-repair defective cells, *Princess Takamatsu Symposia* 13 (1983) 219–226 6317637.
- [49] L. Virág, D.J. Marmer, et al., Crucial role of apoptosis in the peroxynitrite-induced apoptotic DNA fragmentation, *Free Radical Biology and Medicine* 25 (9) (1998) 1075–1082. [http://dx.doi.org/10.1016/S0891-5849\(98\)00139-7](http://dx.doi.org/10.1016/S0891-5849(98)00139-7) 9870561.
- [50] L. Virág, A.L. Salzman, et al., Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death, *Journal of Immunology* (Baltimore, Md.: 1950) 161 (7) (1998) 3753–3759 9759901.
- [51] P.O. Hassa, M.O. Hottiger, The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases, *Frontiers in Bioscience: A Journal and Virtual Library* 13 (2008) 3046–3082. <http://dx.doi.org/10.2741/2909> 17981777.
- [52] S.W. Yu, H. Wang, et al., Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor, *Science* (New York, N.Y.) 297 (5579) (2002) 259–263. <http://dx.doi.org/10.1126/science.1072221> 12114629.
- [53] L. Virág, A. Robaszekiewicz, et al., Poly(ADP-ribose) signaling in cell death, *Molecular Aspects of Medicine* 34 (6) (2013) 1153–1167. <http://dx.doi.org/10.1016/j.mam.2013.01.007> 23416893.
- [54] G.S. Scott, P. Hake, et al., Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis, *Journal of Neuroimmunology* 117 (1–2) (2001) 78–86. [http://dx.doi.org/10.1016/S0165-5728\(01\)00329-0](http://dx.doi.org/10.1016/S0165-5728(01)00329-0) 11431007.
- [55] L. Virág, Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies, *Current Vascular Pharmacology* 3 (3) (2005) 209–214. <http://dx.doi.org/10.2174/1570161054368625> 16026317.
- [56] S.A. Andrabi, G.K. Umanah, et al., Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis, *Proceedings of the National Academy of Sciences of the United States of America* 111 (28) (2014) 10209–10214. <http://dx.doi.org/10.1073/pnas.1405158111> 24987120.